ACRO Biomedical Co Stock

ACRO Biomedical Co DSCR

The Debt Service Coverage Ratio (DSCR) of ACRO Biomedical Co (ACBM) as of Aug 4, 2026 is -0.60. In the previous year, Debt Service Coverage Ratio (DSCR) was -0.29 — a change of 106.39% (lower).

DSCR

-0.60

YoY

106.39%

Last updated:

Debt Service Coverage Ratio (DSCR) of ACRO Biomedical Co is 2026 -0.60 . Debt Service Coverage Ratio (DSCR) of ACRO Biomedical Co was 2025 -0.29 . It decreases by 106.39% lower compared to the previous year.
Access this data via the Eulerpool API

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co Ltd is a leading company in biomedical technology based in Taipei, Taiwan. The company was established in 2006 and has since successfully established itself in the global market for biomedical products and technologies. The company's vision is to improve people's lives and promote health worldwide through innovative and high-quality products and solutions. Business model: ACRO Biomedical Co Ltd specializes in the development, manufacturing, and marketing of biomedical products and technologies. The company has three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology. Each division focuses on developing products and solutions tailored to the needs of patients and medical professionals. Regenerative Medicine: ACRO Biomedical Co Ltd is a leading provider of regenerative biomedical products. Under this division, the company develops innovative solutions for tissue regeneration, such as bioimplants made from natural tissues and biomaterials to repair or restore damaged tissue. These products are used for the treatment of injuries, chronic diseases, and degenerative conditions. Additionally, ACRO Biomedical Co Ltd has also developed solutions for cosmetic and aesthetic applications. Wound Care: ACRO Biomedical Co Ltd's wound care division specializes in developing products and solutions that help accelerate wound healing, prevent infections, and reduce the risk of complications. The company offers a wide range of products, including antimicrobial and moist wound dressings, which are used for the treatment of acute and chronic wounds such as burns, abrasions, and diabetic foot ulcers. Surgical Technology: ACRO Biomedical Co Ltd's surgical technology division provides healthcare professionals with a wide range of surgical products for various applications, including neurosurgery, plastic surgery, and general surgery. The innovative products offered by ACRO Biomedical Co Ltd for surgical applications include cutting tools, implants, and instruments for minimally invasive procedures. Products: ACRO Biomedical Co Ltd offers a wide range of products for various applications and medical specialties. Some of the company's key products include: - ACL-Bioimplant: A bioimplant for cruciate ligament repair made from human cartilage and biomaterials. - ACRO-CAF: A bone grafting material for bone transplantation. - ACRO-Mixtop: A wound healing agent for the treatment of burns, abrasions, and chronic wounds. - ACRO-OSTEOT: A surgical bone drill for orthopedics and neurosurgery. - ACRO-BioSIS: A tissue adhesive for surgical applications. Summary: ACRO Biomedical Co Ltd is a leading company in biomedical technology that offers innovative solutions for the preservation and restoration of people's health. With its three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology, the company provides a wide range of products and solutions for medical professionals and patients. The company's products are marketed worldwide and are known for their quality, reliability, and effectiveness. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ACRO Biomedical Co stock

Debt Service Coverage Ratio (DSCR) of ACRO Biomedical Co is -0.60 in 2026.

Debt Service Coverage Ratio (DSCR) of ACRO Biomedical Co changed from -0.29 to -0.60, representing a 106.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) ACRO Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s ACRO Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co